The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): Randomized phase 2 study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets).
 
Georgina V. Long
Consulting or Advisory Role - Aduro Biotech; Amgen; Array BioPharma; Boehringer Ingelheim; Bristol-Myers Squibb; Hexal; Highlight Therapeutics; Merck Sharpe & Dohme; Novartis; OncoSec; Pierre Fabre; QBiotics; Regeneron; Skyline Diagnostics; Specialised Therapeutics
 
Victoria Atkinson
Honoraria - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Nektar; Novartis; Pierre Fabre; Roche/Genentech
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; QBiotics; Roche
Speakers' Bureau - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Roche/Genentech
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme; OncoSec; Pierre Fabre
 
Serigne Lo
No Relationships to Disclose
 
Alexander David Guminski
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; MSD Oncology; Pfizer; Prime Oncology; Regeneron; Sanofi; Sun Pharma; Tilray
Research Funding - Sun Pharma (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Medivation/Astellas; Merck KGaA; Sun Pharma
 
Shahneen Kaur Sandhu
Honoraria - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Merck Serono (Inst)
Consulting or Advisory Role - Amgen
Speakers' Bureau - Bristol-Myers Squibb; Merck; Roche/Genentech
Research Funding - Amgen (Inst); AstraZeneca (Inst); Endocyte/Advanced Accelerator Applications (Inst); Genentech/Roche (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Michael Paul Brown
Honoraria - Bristol-Myers Squibb (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Roche (Inst)
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb (Inst); MSD (Inst)
 
Maria Gonzalez
No Relationships to Disclose
 
Richard A. Scolyer
Employment - Royal Prince Alfred Hospital
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb GesmbH (Austria); Bristol-Myers Squibb SA (Switzerland); GlaxoSmithKline; Merck Sharp & Dohme; MSD Sharp & Dohme (Australia) Pty Limited; Myriad Genetics; NeraCare GmbH; Novartis; Novartis; QBiotics
Research Funding - National Health and Medical Research Council; National Health and Medical Research Council; The Ainsworth Foundation (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
 
Louise Emmett
No Relationships to Disclose
 
Grant A. McArthur
Research Funding - Genentech/Roche (Inst)
 
Alexander M. Menzies
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; QBiotics; Roche